The area under the concentration-time curve of all-trans-retinoic acid is the most suitable pharmacokinetic correlate to the embryotoxicity of this retinoid in the rat

Toxicology and Applied Pharmacology

Volumn 143, Issue 2, 1997, Pages 436-444

  Tzimas, Georg ^a   Thiel, Renate ^a   Chahoud, Ibrahim ^a   Nau, Heinz ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; RETINOIC ACID; RETINOID; RETINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DOSE TIME EFFECT RELATION; DRUG GLUCURONIDATION; DRUG TISSUE LEVEL; EMBRYO; EMBRYOTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; SKELETON MALFORMATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030890853     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8105     Document Type: Article

References (38)

1. Agnish N. D., Kochhar D. M. Developmental toxicity of retinoids. Retinoids in Clinical Practice: The Risk-Benefit Ratio. 1993;Dekker, New York. p. 47-76.
2. Blaner W. S., Olson J. A. Retinol and retinoic acid metabolism. Sporn M. B., Roberts A. B., Goodman D. S. The Retinoids: Biology, Chemistry, and Medicine. 1994;229-255 Raven Press, New York.
3. Bollag W., Holdener E. E. Retinoids in cancer prevention and therapy. Ann. Oncol. 3:1992;513-526.
4. Clarke D. O., Duignan J. M., Welsch F. 2-Methoxyacetic acid dosimetry-teratogenicity relationships in CD-1 mice exposed to 2-methoxyethanol. Toxicol. Appl. Pharmacol. 114:1992;77-87.
5. Collins M. D., Eckhoff C., Chahoud I., Bochert G., Nau H. 4-Methylpyrazole partially ameliorated the teratogenicity of retinol and reduced the metabolic formation of all-trans. Arch. Toxicol. 66:1992;652-659.
6. Collins M. D., Tzimas G., Hummler H., Bürgin H., Nau H. Comparative teratology and pharmacokinetics of all-transcis. Toxicol. Appl. Pharmacol. 127:1994;132-144.
7. Creech Kraft J., Kochhar D. M., Scott W. J., Nau H. Low teratogenicity of 13-cistrans. Toxicol. Appl. Pharmacol. 87:1987;474-482.
8. Dawson A. A. A note on the staining of the skeleton of cleared specimen with alizarin red S. Stain Technol. 1:1926;123-124.
9. Eckhoff C., Löfberg B., Chahoud I., Bochert G., Nau H. Transplacental pharmacokinetics and teratogenicity of a single dose of retinol (vitamin A) during organogenesis in the mouse. Toxicol. Lett. 48:1989;171-184.
10. Gudas L. J., Sporn M. B., Roberts A. B. Cellular biology and biochemistry of retinoids. Sporn M. B., Roberts A. B., Goodman D. S. The Retinoids: Biology, Chemistry, and Medicine. 1994;443-520 Raven Press, New York.
11. Hummler H., Hendrickx A. G., Nau H. Maternal toxicokinetics, metabolism, and embryo exposure following a teratogenic dosing regimen with 13-cis. Teratology. 50:1994;184-193.
12. Kistler A. Teratogenesis of retinoic acid in rats: Susceptible stages and suppression of retinoic acid-induced limb malformations by cycloheximide. Teratology. 23:1981;25-31.
13. Kochhar D. M. Teratogenic activity of retinoic acid. Acta Pathol. Microbiol. Scand. 70:1967;398-404.
14. Lammer E. J., Chen D. T., Hoar R. M., Agnish N. D., Benke P. J., Braun J. T., Curry C. J., Fernhoff P. M., Grix A. W., Lott I. T., Sun S. C. Retinoic acid embryopathy. N. Engl. J. Med. 313:1985;837-841.
15. Löfberg B., Reiners J., Spielmann H., Nau H. Teratogenicity of steady-state concentrations of etretinate and metabolite acitretin maintained in maternal plasma and embryo by intragastric infusion during organogenesis in the mouse: A possible model for the extended elimination phase in human therapy. Dev. Pharmacol. Ther. 15:1990;45-51.
16. Lotan R. Retinoids in cancer chemoprevention. FASEB J. 10:1996;1031-1039.
17. Maden M. Vitamin A in embryonic development. Nutr. Rev. 52:1994;S3-S12.
18. Mangelsdorf D. J., Umesono K., Evans R. M. The retinoid receptors. Sporn M. B., Roberts A. B., Goodman D. S. The Retinoids: Biology, Chemistry, and Medicine. 1994;319-349 Raven Press, New York.
19. Means A. L., Gudas L. J. The roles of retinoids in vertebrate development. Annu. Rev. Biochem. 64:1995;201-233.
20. Nau H. Teratogenic valproic acid concentrations: Infusion by inplanted minipumps vs. conventional injection regimen in the mouse. Toxicol. Appl. Pharmacol. 80:1985;243-250.
21. Nau H. Species differences in pharmacokinetics and drug teratogenesis. Environ. Health Perspect. 70:1986;113-129.
22. Nau H. Correlation of transplacental and maternal pharmacokinetics of retinoids during organogenesis with teratogenicity. Methods Enzymol. 190:1990;437-448.
23. Nau H. Toxicokinetics and structure-activity relationships in retinoid teratogenesis. Ann. Oncol. 5:1994;S39-S43.
24. Nau H., Chahoud I., Dencker L., Lammer E. J., Scott W. J. Teratogenicity of vitamin A and retinoids. Blomhoff R. Vitamin A in Health and Disease. 1994;615-663 Dekker, New York.
25. Peck G. L., DiGiovanna J. J. Synthetic retinoids in dermatology. Sporn M. B., Roberts A. B., Goodman D. S. The Retinoids: Biology, Chemistry, and Medicine. 1994;631-658 Raven Press, New York.
26. Reiners J., Wittfoht W., Nau H., Vogel R., Tenschert B., Spielmann H. Teratogenesis and pharmacokinetics of the cyclophosphamide after drug infusion as compared to injection in the mouse during day 10 of gestation. Nau H., Scott W. J. Jr. Pharmacokinetics in Teratogenesis. 1987;41-48 CRC Press, Boca Raton.
27. Rosa F. W. Retinoid embryopathy in humans. Koren G. Retinoids in Clinical Practice: The Risk-Benefit Ratio. 1993;77-109 Dekker, New York.
28. Rowland M., Tozer T. N. Clinical Pharmacokinetics. 1989;Lea & Febiger, Philadelphia.
29. Saari J. C. Retinoids in photosensitive systems. Sporn M. B., Roberts A. B., Goodman D. S. The Retinoids: Biology, Chemistry, and Medicine. 1994;351-385 Raven Press, New York.
30. Sass J. O., Zimmerman B., Rühl R., Nau H. Effects of all-transDtransin vitro. Arch. Toxicol. 1997.
31. Shenefelt R. E. Morphogenesis of malformations in hamsters caused by retinoic acid: Relation to dose and stage at treatment. Teratology. 5:1972;103-118.
32. Soprano D. R., Gyda M., Jiang H., Harnish D. C., Ugen K., Satre M., Chen L., Soprano K. J., Kochhar D. M. A sustained elevation of retinoic acid receptor-β2 mRNA and protein occurs during retinoic acid-induced fetal dysmorphogenesis. Mech. Dev. 45:1994;243-253.
33. Terry K. K., Elswick B. A., Stedman D. B., Welsch F. Developmental phase alters dosimetry-teratogenicity relationship for 2methyxyethanol in CD-1 mice. Teratology. 49:1994;218-227.
34. Thiel R., Tzimas G., Dillmann I., Stürje H., Nau H., Chahoud I. Differences in embryotoxicity of all-trans. Teratology. 50:1994;26A.
35. Tzimas G., Thiel R., Plum C., Chahoud I., Nau H. Differences in metabolism and pharmacokinetics of all-transtrans. Teratology. 50:1994a;26A.
36. Tzimas G., Sass J. O., Rühl R., Foerster M., Klug S., Collins M. D., Nau H. Proximate retinoid teratogens. Livrea M. A., Vidali G. Retinoids: From Basic Science to Clinical Applications. 1994b;179-195 Birkhäuser Verlag, Basel.
37. Tzimas G., Bürgin H., Collins M. D., Hummler H., Nau H. The high sensitivity of the rabbit to the teratogenic effects of 13-cisciscistrans. Arch. Toxicol. 68:1994c;119-128.
38. Wilson J. G. Current status of teratology-general principles and mechanisms derived from animal studies. Wilson J. G., Fraser F. C. Handbook of Teratology. 1977;47-74 Plenum, New York.